Group 1 - Hong Kong Exchanges and Clearing CEO stated that simultaneous listings of Greater Bay Area companies in Hong Kong and Shenzhen will help expand investor coverage without diluting market liquidity [1] - The Hong Kong Stock Exchange is currently processing over 160 listing applications, with nearly 20 companies expected to raise over $1 billion each [1] - The Hong Kong Securities and Futures Commission is actively promoting the inclusion of RMB counter in Stock Connect, which is expected to launch by the end of the year [1] Group 2 - Nasdaq China Golden Dragon Index rose by 2.07%, with major US stock indices also showing gains, including a 0.75% increase in the Dow Jones Industrial Average [2] - Popular Chinese concept stocks mostly rose, with Futu Holdings up over 10% and Bilibili up over 5% [2] Group 3 - The National Development and Reform Commission reported that pig prices have hit a 17-month low, with the average price at 14.45 yuan per kilogram, down 1.77% from previous periods [3] Group 4 - Guangdong Province is supporting the innovation and development of radioactive drugs, focusing on new targets and mechanisms for drug research [4] Group 5 - WeChat announced that public accounts can now link to WeChat stores, allowing users to display and sell products directly through their accounts [5] Group 6 - China Shenhua reported a 10.7% year-on-year decrease in coal sales volume for May, attributed to weak downstream demand [6] Group 7 - Hong Kong Broadband announced the establishment of an independent board committee to provide recommendations regarding China Mobile's offer [7] Group 8 - Fosun Pharma and Teva have entered a strategic partnership to jointly develop the anti-PD1-IL2 therapy, with Fosun obtaining exclusive rights for development in China and certain Southeast Asian countries [8] Group 9 - Nanshan Resources expects annual profit to increase from approximately 37.7 million HKD to at least 80 million HKD for the fiscal year ending March 31, 2025 [9] Group 10 - Dongfang Zhenxuan launched its first self-operated sanitary napkin product, achieving sales of over 300,000 packs shortly after launch [10] Group 11 - Zijin Mining and Ajilan Mining are in the process of establishing a joint venture in Saudi Arabia to explore and develop mineral resources [11] Group 12 - Haitan Flavor Industry's IPO in Hong Kong received an oversubscription of approximately 930 times from retail investors [12] Group 13 - China Software International launched its self-developed Hongyun virtual machine, enabling seamless compatibility with Windows software on HarmonyOS [13] Group 14 - China Biopharmaceutical's TDI01 suspension has been included in the breakthrough therapy designation program for treating chronic graft-versus-host disease [14]

Group 1 - Arvinas and Pfizer submitted a New Drug Application (NDA) for Vepdegestrant, the first PROTAC drug to seek approval, targeting advanced or metastatic breast cancer patients with ESR1 mutations [1] - The approval of Vepdegestrant could fill a significant treatment gap in the breast cancer market, attracting substantial investment and enhancing the overall industry valuation [1] Group 2 - Beijing Tide Pharmaceutical's TDI01 has been proposed for inclusion as a breakthrough therapy for chronic graft-versus-host disease (cGVHD), indicating its potential in a complex treatment area [2] - TDI01 is a novel ROCK2 inhibitor, and its breakthrough designation could significantly enhance the company's valuation and attract investor interest, bolstering China's innovative drug competitiveness [2] Group 3 - Anke Biotech anticipates significant sales growth for its trastuzumab product, Ansaiting, projecting over 100 million yuan in revenue for 2024 [3] - The positive market performance of Ansaiting enhances Anke Biotech's position in the oncology sector, potentially attracting more investors and supporting future research and market expansion [3] Group 4 - Haiwang Bio announced the termination of its control change and stock issuance, indicating ongoing discussions with state-owned entities for potential equity cooperation [4] - The proactive approach to resource integration and business collaboration may create new growth opportunities for Haiwang Bio, positively influencing market perceptions of its long-term value [4] Group 5 - Green Valley Pharmaceutical has ceased production of its Alzheimer's drug, Ganluo Sodium Capsules, following concerns over its efficacy and safety [6] - The shutdown reflects significant operational adjustments for the company, potentially leading to investor concerns about its future prospects and market confidence [6]